CD5 expression by IHC / flow cytometry
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-CD5-IHC |
|---|---|
| Type | Biomarker |
| Aliases | CD5 expressionЕкспресія CD5 (ІГХ / проточна цитометрія) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC on FFPE biopsy OR flow cytometry on PB/BM Unitscategorical (positive | negative) |
| Related biomarkers | BIO-CD23-IHC BIO-CCND1-IHC |
Notes
Cross-disease relevance — CD5+ B-cell lineage marker: - **CLL/SLL** (defining): CD5+ CD23+ classic immunophenotype - **MCL** (defining): CD5+ CD23− cyclin-D1+ — distinguishes from CLL - **DLBCL**: CD5+ DLBCL is adverse subset (~5-10%) — worse R-CHOP outcomes - **Burkitt** typically CD5− - **FL** typically CD5− - **MZL** typically CD5− - **PTCL** also CD5+ (T-cell marker; differential context) Used primarily for diagnostic differentiation rather than algorithm routing. CD5+ DLBCL future scope: candidate for early CAR-T pathway consideration.
Used By
Biomarker
BIO-CCND1-IHC- Cyclin D1 expression by IHC (encoded by CCND1)BIO-CD23-IHC- CD23 expression by IHC / flow cytometry
Indications
IND-CLL-1L-BTKI- IND-CLL-1L-BTKIIND-CLL-1L-VENO- IND-CLL-1L-VENOIND-CLL-1L-ZANUBRUTINIB- IND-CLL-1L-ZANUBRUTINIBIND-MCL-1L-BTKI-R- IND-MCL-1L-BTKI-RIND-MCL-1L-INTENSIVE- IND-MCL-1L-INTENSIVEIND-MCL-2L-ACALABRUTINIB- IND-MCL-2L-ACALABRUTINIB
Questionnaires
QUEST-MCL-1L-STUB- Mantle Cell Lymphoma — first line